Intelligent Searching Tool Enables Biochemical Lead Identification and Patent Fortification
By LabMedica International staff writers Posted on 29 Jan 2013 |
A new intelligent database searching system provides virtual screening to identify biologically active molecules for a broad range of applications.
Cresset Group (Welwyn Garden City, UK) completes its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as “blazeV10” for ligand based virtual screening. Based on the shape and electrostatic character of known ligands, blazeV10 rapidly searches large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.
blazeV10 is used to find biologically active molecules in a broad range of situations across the pharmaceutical, agrochemical, and fine chemical industries. Performing a virtual screen with blazeV10 before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results identifies molecules, which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential reprofiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.
“The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10, and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research,” said Dr. Robert Scoffin, CEO of Cresset.
blazeV10 is operated through a simple web based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.
Related Links:
Cresset Group, Ltd.
Cresset Group (Welwyn Garden City, UK) completes its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as “blazeV10” for ligand based virtual screening. Based on the shape and electrostatic character of known ligands, blazeV10 rapidly searches large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.
blazeV10 is used to find biologically active molecules in a broad range of situations across the pharmaceutical, agrochemical, and fine chemical industries. Performing a virtual screen with blazeV10 before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results identifies molecules, which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential reprofiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.
“The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10, and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research,” said Dr. Robert Scoffin, CEO of Cresset.
blazeV10 is operated through a simple web based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.
Related Links:
Cresset Group, Ltd.
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples